secwatch.observer — SEC 8-K summary
======================================

Issuer:     Structure Therapeutics Inc. (GPCR)
CIK:        0001888886
Form:       8-K
Filed at:   2023-08-04T23:59:59+00:00
Accession:  0001104659-23-087873
Event type: leadership
Sentiment:  positive
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Appoints Ted Love, M.D. to Board; amends director compensation policy
---------------------------------------------------------------------

- Ted Love, M.D. appointed as Class III director and Chair of Compensation Committee effective August 3, 2023.
- Board size reduced to seven directors; Love determined independent under Nasdaq listing standards.
- Initial option grant for new non-employee directors increased to 75,000 ordinary shares (25,000 ADSs).
- Annual option grant set at 37,500 ordinary shares (12,500 ADSs); post-termination exercise period extended for trust transfers.
- Love receives initial grant of 75,000 shares vesting over 36 months plus cash retainers of $45,000 and $10,000.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1888886/000110465923087873/0001104659-23-087873-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1888886/000110465923087873/tm2322858d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-087873

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer